drugset / Trial / NCT01804634
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Phase 2
Recruiting
60 enrolled
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to see if giving reduced intensity chemotherapy, haploidentical bone marrow, post-transplant cyclophosphamide and shortened duration tacrolimus is safe and feasible for patients with very high-risk solid tumors.
Timeline
- Start
- 2013-03-27
- Primary completion
- 2027-01
- Completion
- 2030-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 50 mg/kg | Intravenous |
| Subject | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |
| Subject | Melphalan | Small molecule | 100 mg/m2 | Intravenous |
| Subject | Tacrolimus | Small molecule | 0.015 mg/kg | Oral |